TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A MedPage Today neurology roundup summarized three separate research developments: a study examining head shape and Alzheimer’s pathology, a randomized trial of prenatal phosphatidylcholine and children’s outcomes, and an analysis of aspirin use and dementia risk. The findings are preliminary or limited in scope and do not establish that head shape predicts Alzheimer’s, that supplements should be used in pregnancy, or that aspirin prevents dementia.
MedPage Today’s October 27 neurology roundup highlighted three studies relevant to Alzheimer’s disease and brain health: research on whether head shape relates to Alzheimer’s pathology, a prenatal phosphatidylcholine trial reporting differences in some children’s outcomes through age 4, and an analysis suggesting platelet-related genetic profiles may affect aspirin’s possible role in dementia prevention. The roundup summarizes findings from separate studies; none establishes a new clinical recommendation.
The report’s headline asks whether head shape can influence Alzheimer’s disease pathology and cites an item published in the journal Alzheimer’s & Dementia. The supplied summary does not describe the study’s methods, participants, results, or whether it found an association. It therefore does not establish that head shape causes Alzheimer’s disease or can be used to assess an individual’s risk.
A randomized trial reported that prenatal phosphatidylcholine supplementation was associated with fewer social withdrawal problems and higher IQ test performance in offspring through age 4. The report says the supplements did not reduce attention problems. It does not provide the size of the effects, the number of participants, or details about the supplement regimen, so the findings cannot by themselves guide decisions about supplementation during pregnancy.
The third item summarized ASPREE trial data suggesting that platelet count polygenic scores may influence how aspirin relates to dementia prevention. The report says this could mean certain groups of older adults may benefit, but it gives no effect estimates or subgroup details. The finding is a suggestion from an analysis, not evidence that aspirin prevents dementia for older adults generally.
What the Three Findings Could Mean
Together, the studies point to different questions about risk, early development, and prevention, but they are not interchangeable evidence. Head-shape research concerns a possible relationship with Alzheimer’s pathology; the pregnancy trial tracks children’s outcomes; and the aspirin analysis considers whether inherited differences might modify an association with dementia. Each requires its own assessment of methods and limitations.
The prenatal trial is relevant to families because it reports outcomes beyond birth, including IQ test performance and social withdrawal through age 4. But a report of higher test scores in one trial does not establish that supplementation will produce the same result for every child or that it improves long-term development. Pregnant people should discuss supplement use with a qualified health professional rather than treating this summary as medical advice.
The aspirin finding could matter because it raises the possibility that effects differ among subgroups, rather than applying equally to everyone. However, without reported effect sizes, clinical outcomes, and details of the analysis, readers cannot judge how substantial the potential difference is. The roundup does not support starting aspirin to prevent dementia.
Popular right now
Roborock Robot Vacuum and Mop with LiDAR Navigation and 10,000 Pa Suction
Roborock RockNeo Q110H Wire-Free Robot Lawn Mower
Breville Bambino Espresso Machine, Brushed Stainless Steel
As an affiliate, we earn on qualifying purchases.
Separate Studies, Separate Evidence
The source is a short neurology and neuroscience news roundup by Judy George, MedPage Today’s deputy managing editor, published October 27, 2026. It brings together findings from multiple journals rather than reporting a single coordinated study. The three topics in the headline are only part of a broader list of research and coverage items.
The other items in the roundup include the launch of the U.K. AD-Smart Alzheimer’s platform trial, which is set to test repurposed medicines beginning with metformin and atomoxetine; research into the enzyme PLA2G2F and cognitive resilience; and a cohort study reporting a later mean age of amyloid onset among Black participants than white participants. Those are separate developments and do not confirm the three headline findings.
Because the supplied report is brief, it provides no study-level detail for the head-shape item, the prenatal trial, or the ASPREE analysis beyond their broad conclusions. The journal names are given for the prenatal and head-shape items, while the aspirin item is described as using ASPREE trial data. Readers need the underlying papers to evaluate design, sample sizes, and the strength of the evidence.
Study Details Still Missing
The supplied roundup does not identify the methods, sample sizes, or effect estimates for the head-shape research or the ASPREE analysis. It also does not explain what measure of head shape was studied, how Alzheimer’s pathology was assessed, or which genetic-score groups were associated with a different aspirin effect. Those omissions prevent a detailed appraisal of the findings.
For the prenatal trial, the report does not state the number of participants, supplement dose, comparison group, or size of the reported differences. It also gives no results beyond age 4. The summary therefore cannot show whether the observed changes were large, lasting, or applicable to people outside the study population.
Across all three topics, it remains unclear whether the findings will be replicated or change clinical practice. The roundup does not report a recommendation from researchers or health authorities to use head shape for risk assessment, take prenatal phosphatidylcholine, or use aspirin for dementia prevention.
Full Papers and Follow-Up Evidence
The next step for readers seeking detail is to consult the underlying journal papers, particularly for study design, participant characteristics, effect sizes, and stated limitations. Further research would be needed to establish whether any head-shape association is reproducible and clinically useful, and whether the prenatal trial’s child outcomes persist beyond the reported follow-up.
For aspirin, the reported genetic-score finding would need additional analysis and independent confirmation before it could support decisions about dementia prevention for particular groups. The roundup does not give a timeline for such research or identify a new clinical guideline. Until more evidence is available, it reports research signals rather than changes in care.
Key Questions
Does the head-shape study show that head shape causes Alzheimer’s?
No such conclusion is supported by the supplied summary. It says the study examined whether head shape can influence Alzheimer’s pathology but provides no methods or results establishing causation.
What did the prenatal phosphatidylcholine trial report?
The report says supplementation was associated with fewer social withdrawal problems and higher IQ test performance in children through age 4, but did not reduce attention problems. It does not provide effect sizes or enough detail to guide supplement use.
Should older adults take aspirin to prevent dementia?
The roundup does not recommend aspirin for dementia prevention. It describes an ASPREE-data analysis suggesting that platelet count polygenic scores may influence a possible effect in some subgroups; people should discuss aspirin with a qualified clinician.
Are these three findings from one study?
No. They are separate research items summarized in a MedPage Today neurology roundup, involving different topics and evidence sources.
Source: medpagetoday.com
